pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

CSL Behring LLC

updated 5mo ago

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.

community read0 votes
pipeline
10
marketed
10
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(10)

pipeline depth10 products
Marketed: 10
10Marketed
Marketed
(coagulation factor VIII (human) + von willebrand factor complex (human))
Hemophilia A (Factor VIII Deficiency)
Marketed
C1 esterase inhibitor (human)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Marketed
Haegarda
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Marketed
Kcentra
Bleeding And Clotting Disorders
Marketed
albutrepenonacog alfa LA
Hemophilia B (Factor IX Deficiency)
Marketed
antihemophilic factor (recombinant), single chain
Hemophilia A (Factor VIII Deficiency)
Marketed
cytomegalovirus immune globulin (human)
Cytomegalovirus (HHV-5) Infections
Marketed
etranacogene dezaparvovec
Hemophilia B (Factor IX Deficiency)
Marketed
factor XIII (human)
Fibrin Stabilizing Factor Deficiency (Factor XIII Deficie…
Marketed
garadacimab
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view CSL Behring LLC jobs →

News

  • Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trial
    Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
    fiercebiotech · 4d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 7d ago
  • STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and more
    In today's Pharmalittle newsletter, drug pricing deals, a new cancer therapy approval, and more of the latest pharma headlines.
    stat · 2mo ago
  • Chiesi to buy KalVista in $1.9B deal for rare disease drug
    The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
    biopharma_dive · 6mo ago
  • Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
    The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.
    biopharma_dive · 6mo ago
identifiers
source
globaldata
top tags
Immunology2Infectious Disease1
mentioned in
5news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?